

Vaccine 3rd Global Congress

Sunday Oct. 4, 2009

09:00 Conference Registration | *Grand Gallery*

11:00 – 12:55 **Opening Session & Plenary Session 1** | *Grand Ballroom*

Session Chair: Shan Lu

Opening remarks: Ray Spier

11:10 [O1.1] Polio – a crippler that is down but not out

Walt Orenstein, *Gates Foundation, USA*

11:50 [O1.2] New approaches for live attenuated influenza virus vaccines based on NS1 modification

Adolfo Garcia-Sastre, *Mount Sinai School of Medicine, USA*

12:30 [O1.3] Introduction of new vaccines into low income countries - a WHO perspective

Joachim Hombach, *WHO Initiative for Vaccine Research, Switzerland*

13:00 – 14:00 Lunch | *Grand Gallery*

13:10 – 13:55 **SciVal Funding Workshop** | *Millenia 3*

14:00 – 15:35 **Plenary session 2** | *Grand Ballroom*

Control major infectious diseases in developing countries

Session Chair: Prasert Thongcharoen

14:00 [O2.1] Developing country and vaccines for diseases prevention and control

Supachai Rerks-Ngarm¹, P. Thongcharoen², P. Kunasol¹; ¹Ministry of Public Health, Thailand, ²Mahidol University, Bangkok, Thailand

14:25 [O2.2] The RTS,S Malaria Vaccine candidate: Getting closer to the goal

Joe Cohen, *GlaxoSmithKline Biologicals, Belgium*

14:50 [O2.3] New developments and controversies in rabies

Henry Wilde, *Chulalongkorn University, Thailand*

15:15 [O2.4] A novel therapeutic and prophylactic vaccine (HVJ-Envelope/Hsp65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model

M. Okada^{*1}, E.V. Tan², et al; ¹National Hospital Organization Kinki-chuo Chest Medical Center, Japan, ²Leonard Wood Memorial Institute, Philippines

15:25 [O2.5] Mumps Vaccines: past, present and future?

C. Vandermeulen¹, G. Leroux-Roels², P. Van Damme³, K. Hoppenbrouwers¹; ¹K.U.Leuven, Belgium, ²Ghent University, Belgium, ³University of Antwerp, Belgium

15:35 – 16:05 Refreshment Break | *Grand Gallery*

16:10 – 18:00 **Plenary session 3** | *Grand Ballroom*

Scientific research of vaccines

Session Chair: Jennelle Kyd

16:10 [O3.1] New Prospect for Mucosal Vaccine Development: MucoRice and MucoNanogel

Hiroshi Kiyono, *University of Tokyo, Japan*

16:35 [O3.2] Strategies towards vaccination against herpesviruses

Ed Mocarski, *MedImmune, USA*

17:00 [O3.3] The end of the Jennerian Era in making vaccines? New insights from deceptive imprinting and immune refocusing technology for making novel immunobiotics

Greg Tobin, *Biological Mimetics, Inc. USA*

17:25 [O3.4] Redemption from original antigenic sin responses to influenza viruses

J.H. Kim, J. Jacob^{*}; *Emory University, USA*

17:35 [O3.5] Analysis of immunity to a chimpanzee adenovirus vector in a paediatric cohort

M.S. Dudareva^{*1}, L. Andrews¹, P. Bejon², S.C. Gilbert¹, J. Mwacharo², O. Kai², et al; ¹Oxford University, UK, Kenya Medical Research Institute, Kenya

17:45 [O3.6] Analysis of the mechanism by which BALB/c mice having prior immunization with nucleocapsid protein of SARS-CoV develop severe pneumonia after SARS-CoV infection

F. Yasui^{*1}, C. Kai², K. Saito¹, S. Inoue³, M. Yoneda², K. Morita³, et al; ¹Tokyo Metropolitan Institute of Medical Science, Japan, ²University of Tokyo, Japan, ³Nagasaki University, Japan

18:00 – 19:30 Poster/Exhibition Session 1 and Welcome Reception | *Grand Gallery*

09:00 - 10:30

Plenary session 4 | Grand Ballroom
Adjuvants and immune protection

Session chair: David Weiner

09:00

[O4.1] The road to adjuvanted vaccines: A status
Nathalie Garcon, *GlaxoSmithKline Biologicals, Belgium*

09:25

[O4.2] ISCOMATRIX™ adjuvant provides an avenue to overcome immunosenescence in the elderly
Eugene Maraskovsky, *CSL Ltd, Australia*

09:50

[O4.3] T-cell epitopes are sufficient to provide protection against lethal vaccinia challenge in HLA transgenic mice
L. Moise^{1,2}, J. Schriewer³, W. Martin¹, J. Lee⁴, M. Buller³, A. De Groot^{*1,2}, et al; ¹EpiVax, Inc, USA, ²University of Rhode Island, USA, ³St. Louis University, USA, ⁴University of Massachusetts Medical Center, USA

10:00

[O4.4] AS03 adjuvant system prepares the immune system for a fast and strong immune response after vaccination with a heterologous H5N1 influenza vaccine
F. Roman¹, J. Leroux-Roels², G. Leroux-Roels², M. Drame¹, P. Gillard^{*1}; ¹GlaxoSmithKline Biologicals, Belgium, ²Center of Vaccinology, Belgium

10:10

[O4.5] Final results of a phase I study with a Her-2/neu multi-peptide virosome vaccine in patients with metastatic breast cancer
U. Wiedermann^{*1}, C. Witschke¹, J. Jansinska^{1,3}, R. Zurbriggen², M. Kundi¹, E. Garner-Spitzer¹, R. Bartsch¹, O. Scheiner^{1,3}, C.C. Zielinski^{1,3}; ¹Medical University Vienna, Austria, ²Pevion Biotech, Switzerland, ³BioLife Science, Austria

10:20

[O4.6] Vaccination and allergy: The right choice of the adjuvant system as well as the time point of vaccination might influence allergy development
A. Wagner^{*1}, B. Winkler¹, I. Schabussova¹, C. Herzog², U. Wiedermann¹, ¹Medical University of Vienna, Austria, ²Berna Biotech Crucell, Switzerland

10:30 - 11:00

Refreshment Break | Grand Gallery

11:00 - 12:30

GlaxoSmithKline Satellite Symposium | Grand Ballroom

12:30 - 13:40

Poster/Exhibition Session 2 + Lunch | Grand Gallery

13:00 - 13:30

ISV Business Meeting
Ray Spier, Shan Lu and Adolfo Garcia-Sastre

13:40 - 15:10

Plenary sessions 5 | Grand Ballroom
Novel vaccines and delivery systems

Session Chair: John Shiver

13:40

[O5.1] Improved immune responses induced by engineered DNA vaccines
David Weiner, *University of Pennsylvania, USA*

14:05

[O5.2] Issues and challenges in vaccine delivery faced by the new WHO technologies and logistics advisory committee
Bruce Weniger, *Centers for Disease Control and Prevention, USA*

14:30

[O5.3] Vaccine development against enterovirus 71 using live attenuated Bordetella pertussis as a nasal delivery system
W.X. Khong^{*}, S. Alonso, *National University of Singapore, Singapore*

14:40

[O5.4] Development of a mucosal vaccination platform for ebola
J. Dekker¹, J.H. Choi¹, S. Renteria¹, J. Richardson², G. Kobinger², C. Clemens¹, M.A. Croyle^{*1,2}, et al; ¹The University of Texas at Austin, USA, ²PHAC, Canada

14:50

[O5.5] Immunoadjuvant efficacy of interleukin-18 co-administration with Newcastle Disease vaccine in chickens
L.H. Hung^{*1,2}, H.P. Li¹, S.L. Li¹, I.Y. Lien¹, H.C. Chaung¹; ¹National Pingtung University of Science and Technology, Taiwan, ²Kaohsiung Biological Product Co. Ltd., Taiwan

15:00

[O5.6] IMVAMUNE® (MVA-BN®) vaccine protects nonhuman primates from aerosolized monkeypox virus
A. Nalca^{*}, V. Livingston, N. Garza, O. Espenshade, J. Hartings, J. Chapman, et al; *USAMRIID, USA*

15:10 - 15:40

Refreshment Break | Grand Gallery

15:40 - 17:30

Break out sessions 1, 2 & 3**Breakout Session 1 | Millenia Room 2**
JSV sponsored session and Influenza

Session chair: Hiroshi Kyono

15:40

[B1.1] Live Attenuated Novel H1N1 Influenza Vaccines
Hong Jin, *MedImmune, USA*

- 16:00** [B1.2] **Flu sublingual immunization**
Mi-Na Kweon; *International Vaccine Institute, Korea*
- 16:20** [B1.3] **Plasmacytoid dendritic cells prime influenza vaccine immunogenicity**
Ken J. Ishii^{1,2}, S. Koyama^{1,5}, T. Aoshi², T. Tanimoto³, Y. Kumagai¹, K. Kobiyama², K. Sakurai⁴, C. Coban¹, T. Hori², S. Akira¹; ¹WPI Immunology Frontier Research Center, Japan, ²Osaka University, Osaka, Japan, ³The Research Foundation for Microbial Diseases of Osaka University, Japan, ⁴The University of Kitakyushu, Japan, ⁵Tohoku University Graduate School of Medicine, Japan
- 16:40** [B1.4] **Evaluation of an avian influenza H5N1 porcine adenovirus-based vaccine**
A. Patel^{1,2}, S. Tikoo³, D. Kobasa^{1,2}, G. Kobinger^{1,2}; ¹University of Manitoba, Canada, ²Public Health Agency of Canada, Canada, ³University of Saskatchewan, Canada
- 16:50** [B1.5] **IgG-binding Fc receptors and alveolar macrophages are involved in anti-M2e antibody-mediated immune protection**
X. Saelens^{1,2}, K. El Bakkouri^{1,2}, F. Descamps^{1,2}, M. De Filette^{1,2}, N. Van Rooijen⁴, S. Verbeek³, et al; ¹VIB, Belgium, ²Ghent University, Belgium, ³Leiden University Medical Center, The Netherlands, ⁴Vrije Universiteit, The Netherlands
- 17:00** [B1.6] **New approach to influenza vaccine purification**
E. Maurer¹, M. Peterka², M. Gassner¹, M. Banjac¹, A. Strancar¹, C. Lim¹, et al; ¹Avir Green Hills Biotechnology, Austria, ²BIA Separations, Slovenia
- 17:10** [B1.7] **Fabrication of virus-like particles from human and avian influenza viruses**
S.-C. Wu^{1,2}, H.-R. Wei¹, S.-C. Lin¹, F.A.-H. Chou², W.-H. Chang³, D.-K. Chang³, et al; ¹National Tsing Hua University, Taiwan, ²Sinica Vaccine Research and Development Center, NHRI, Taiwan, ³Institute of Chemistry Academia, Taiwan
- 17:20** [B1.8] **Broadly cross-neutralizing immune responses to different clades of the influenza virus elicited by novel SynCon(TM) DNA vaccines delivered via electroporation**
N. Y. Sardesai¹, J. Yan², D. Laddy², A. Khan¹, P. Brown¹, D.B. Weiner², et al; ¹Inovio Biomedical Corporation, USA, ²University of Pennsylvania, USA

Breakout Session 2 | Grand Ballroom
Flavivirus vaccines

Session Chairs: Mansour Yaich & Beth Collier

- 15:40** [B2.1] **Preclinical and clinical evaluation of YF 17D-based chimeric vaccines against Dengue, Japanese encephalitis and West Nile viruses**
Bruno Guy¹, F. Guirakhoo¹, V. Barban¹, S. Higgs², T.P. Monath³, J. Lang¹; ¹Sanofi pasteur, France; ²University of Texas Medical Branch, USA; ³Kleiner Perkins Caufield & Byers, USA
- 16:00** [B2.2] **Recombinant subunit vaccines for flaviviruses**
Beth Ann Collier*, D. Clements, S. Ogata, T. Martyak, M. Thorne, R. Henley, M. O'Connell, D. Bronesky D. Elliot Parks; *Hawaii Biotech, Inc. USA*
- 16:20** [B2.3] **JE vaccine**
Katrín Dubischar-Kastner, *Intercell, Austria*
- 16:40** [B2.4] **Increasing access to safe and affordable JE vaccines**
Mansour Yaich, *PATH Immunization Solutions, USA*
- 17:00** [B2.5] **Effectiveness of an immunization program using a low-dose, mouse brain-derived, inactivated Japanese encephalitis vaccine in Northern Vietnam**
F. Marks¹, T.T.Y. Nguyen², D.T. Nhu², M.H. Nguyen², H.H. Vu², R. Gibbons³, et al; ¹International Vaccine Institute, Republic of Korea, ²National Institute for Hygiene and Epidemiology, Vietnam, ³American Forces Research Institute for Medical Sciences, Thailand
- 17:10** [B2.6] **Development of dengue vaccines: A global perspective on regulatory issues**
R.T. Mahoney¹, J. Southern², L. Chocarro², D.P. Francis³, J. Vose⁴, H.S. Margolis¹; ¹International Vaccine Institute, Republic of Korea, ²World Health Organization, Switzerland, ³Global Solutions for Infectious Diseases, USA, ⁴Consultant, France, ⁵Advisor Medicines Control Council, South Africa
- 17:20** [B2.7] **Humanized mice: Recent development**
M. Khoury^{1,2}, Q. Chen¹, A. Drake², I. Leskov², J. Chen^{1,2}; ¹Infectious Disease IRG, Singapore, ²Koch Institute for Integrative Cancer Research, USA

Breakout Session 3 | Millenia Room 3
Neglected diseases

Session Chair: Shan Lu

- 15:40** [B3.1A] **To be announced**
- 15:50** [B3.1B] **To be announced**
- 16:00** [B3.2] **Vaccination against *Taenia solium* Cysticercosis in pigs using recombinant oncosphere antigen TSOL18**
X. Cai, X. Luo, S. Zhang; *Lanzhou Veterinary Research Institute, China*
- 16:10** [B3.3] **Alginate microspheres encapsulated with Autoclaved *Leishmania major* (ALM) and CpG-ODN induced high immune responses against leishmaniasis**
M. Tafaghodi*, M.-R. Jaafari, M. Eskandari, A. Khamesipour; *Mashhad University of Medical Sciences, Iran*
- 16:20** [B3.4] ***Rickettsia prowazekii* shares homology with human sequences that have implications in vaccine development and pathogenesis**
J. Dong*; *University of Texas Medical Branch, USA*
- 16:30** [B3.5] **Vaccination against fasciolosis by a multivalent vaccine of recombinant stage-specific antigens**
R. Jayaraj¹, D. Piedrafita², K. Dynon², R. Grams³, T.W. Spithill⁴, P.M. Smooker¹; ¹RMIT University, Australia, ²Monash University, Australia,

- 16:40 **[B3.6] A multivalent vaccine approach for lymphatic filariasis**
K. Ramaswamy*¹, D. Gajalakshmi², V. Anandharaman¹, M. Gnanasekar¹, M.V.R. Reddy²; ¹University of Illinois, USA, ²Mahatma Gandhi Institute of Medical Sciences, India
- 17:30 **Merck and Wellcome Talk: The New Vaccine Center**
John Shiver, Merck, USA
- 18:30 – 22:30 **Congress Gala Dinner (optional)**

Tuesday Oct 6, 2009

- 09:00 – 09:30 **Plenary sessions 6 | Grand Ballroom**
ISV president's presentation, Ray Spier
- 09:30 – 10:10 **Plenary session 6 Continued | Grand Ballroom**
Late Breakers Abstracts
Session Chair: Ray Spier
- 09:30 **[O6.1] Comparison of herpes zoster incidence between adults not vaccinated and vaccinated with a zoster vaccine**
H.F. Tseng*, N. Smith, L.S. Sy, S.J. Jacobsen; *Kaiser Permanente, USA*
- 09:40 **[O6.2] Glycoengineered yeast as a novel platform for the development of next-generation subunit vaccines**
D. Casimiro*, R. Davidson, V. Copeland, J. Balliet, J. Flynn, M. Brown, et al; *Merck & Co, USA*
- 09:50 **[O6.3] Peptide-based vaccine against EV71 infection**
S.P. Lien*, P. Chong, S.J. Liu, et al; *National Health Research Institutes, Taiwan*
- 10:00 **[O6.4] Novel Vaccine Candidates for Chikungunya Fever**
A.P. Adams*¹, E. Wang¹, E. Volkova², K. Plante¹, R. Gorchakov¹, N. Forrester¹, et al; ¹University of Texas Medical Branch, USA, ²University of Alabama, USA
- 10:10 – 10:40 **Refreshment Break | Grand Gallery**
- 10:40 – 12:10 **Plenary session 7 | Grand Ballroom**
Bacterial vaccines
Session Chair: Bruce Weniger
- 10:40 **[O7.1] Pneumococcal Conjugate Vaccines and antibiotic consumption – who will win the antibiotic resistance battle?**
Ron Dagan, *Ben-Gurion University of the Negev, Israel*
- 11:05 **[O7.2] Reducing the burden of bacterial respiratory infections: Current challenges to vaccine strategies**
Jennelle Kyd, *Central Queensland University, Australia*
- 11:30 **[O7.3] Hospitalised, acute lower respiratory infections in Australian Indigenous infants primed with the 7-valent pneumococcal conjugate vaccine in infancy and boosted with the 23-valent pneumococcal polysaccharide vaccine at 18 months of age**
K. O'Grady*¹, K. Lee², J. Carlin², A. Chang¹, P. Torzillo³, K. Mulholland^{1,4}, et al; ¹Charles Darwin University, Australia, ²Murdoch Children's Research Institute, Australia, ³University of Sydney, Australia, ⁴London School of Hygiene and Tropical Medicine, UK
- 11:40 **[O7.4] Characterization of Salmonella-specific CD4 T cells to oral infection or vaccination**
S. McSorley*, A. Griffin, S.-J. Lee, J. McCarra; *University of Minnesota, USA*
- 11:50 **[O7.5] Development of an efficient and scalable method for processing and purification of Vi capsular polysaccharide**
S. Kothari*, K. Neha, L. Eugene, C. Rodney, et al; *International Vaccine Institute, Republic of Korea*
- 12:00 **[O7.6] Cell membrane immunogens of a biofilm-producing staphylococcus aureus isolate adjuvanted with bacterial chromosomal DNA are protective in a mouse mastitis model**
K. Sharma*, A. Singh; *Ch. Charan Singh Haryana Agric. University, India*
- 12:10 – 13:20 **Poster/Exhibition Session 3 + Lunch | Grand Gallery**
- 13:20 – 14:50 **Plenary sessions 8 | Grand Ballroom**
New human and veterinary vaccine pipelines
Session Chair: Adolfo Garcia-Sastre
- 13:20 **[O8.1] Opportunities and Challenges for Developing New Vaccines: "A Merck Perspective"**
John Shiver, *Merck, USA*
- 13:45 **[O8.2] Pandemic Influenza Vaccines: Working around the clock**
K. Stohr¹, W. Bender², N. Groth³, T.Tsai*¹; *Novartis Vaccines and Diagnostics, USA¹, Novartis Vaccines and Diagnostics, Germany², Novartis Vaccines and Diagnostics, Italy³*
- 14:10 **[O8.3] The promotion of the immunity of piglets to Hog cholera vaccine by shuffled pig interleukin-2 gene and CpG immunostimulatory sequences encapsulated in chitosan nanoparticles**
J.-L. Chen, X.-P. Wan, X. Yang, H. Zhang, W.-L. C.R. Gao*, et al; *Sichuan University, China*

- 14:20 **[O8.4] Development and application of Porcine Epidemic Diarrhea oral vaccine**
D.S Song*¹, B.K Kang¹, J.M Kim¹, B.K Park^{1,2}; ¹Green Cross Veterinary Products, Republic of Korea, ²Seoul National University, Republic of Korea
- 14:30 **[O8.5] Improving the potency of DNA vaccine against chicken Anemia Virus (CAV) by fusing of VP1 protein of CAV to Marek's Disease Virus (MDV) Type-1 VP22 protein**
H. Moeini*, K. Yusoff, A.R. Omar, R. Abdul Rahim; *University Putra Malaysia, Malaysia*
- 14:40 **[O8.6] The intestinal receptor for F4 enterotoxigenic E. coli in pigs can serve as a target to induce intestinal immunity against enteropathogens**
E. Cox*¹, V. Melkebeek¹, K. Rasschaert¹, P. Bellot¹, F. Verdonck¹, B.M. Goddeeris^{1,2}, et al; ¹Gent University, Belgium, ²Leuven University, Belgium
- 14:50 – 15:20 **Refreshment Break | Grand Gallery**
- 15:20 – 17:30 **Plenary sessions 9 | Grand Ballroom**
Responses to future challenges
- 15:20 Annie De Groot
- 15:20 **[O9.1] Vaccine research partnership with developing countries**
Shan Lu, *University of Massachusetts Medical School, USA, Nanjing Medical University, China*
- 15:45 **[O9.2] Immunological correlates of protection**
Andrew Dunning, *Sanofi Pasteur, Swiftwater, USA*
- 16:10 **[O9.3] Decrease of hepatitis B virus infection and hepatocellular carcinoma in children and beyond: Impacts of hepatitis B vaccination in Taiwan**
Ding-Shinn Chen, *National Taiwan University, Taiwan*
- 16:35 **[O9.4] Challenges and Responses of China AIDS Vaccine Research**
Yong Liu, *National Center for AIDS/STD Control and Prevention, China*
- 17:00 **[O9.5] Financial sustainability of Global Health Partnership programs: Evidence from GAVI's injection safety support**
A. Bchir*¹, A. Levin², O. Dia², A. Fang¹, N. Schwalbe¹; ¹GAVI Alliance, Switzerland, ²JSI Research & Training Inc, USA
- 17:20 **Closing Summary**
Ray Spier and Shan Lu